Conference abstract
Conference abstractPublished 18 Aug 2016
2016 WHO clinical molecular and pathological criteria for classification and staging of myeloproliferative neoplasms (MPN) caused by MPN driver mutations in the JAK2, MPL and CALR genes in the context of new
Goodheart Institute, Netherlands
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The 2016 WHO-CMP classification proposal defines a broad spectrum of JAK2 V617F mutated MPN phenotypes: Normocellular ET, hypercellular ET due to increased erythropoiesis (prodromal PV), hypercellular ET with megakaryocytic-granulocytic myeloproliferation and splenomegaly (EMGM or masked PV), erythrocythemic PV, early and overt classical PV, advanced PV with MF and post-PV MF. ET heterozygous for the JAK2 V617F mutation is associated with low JAK2 mutation load and normal life expectance. PV patients are hetero-homozygous versus homozygous for the JAK2 V617F mutation in their early versus advanced stages with increasing JAK2 mutation load from less than 50% to 100% and increase of MPN disease burden during lifelong follow-up in terms of symptomatic splenomegaly, constitutional symptoms, bone marrow hypercellularity and secondary MF. Pre-treatment bone marrow biopsy in prefibrotic MPNs is of diagnostic and prognostic importance. JAK2 exon 12 mutated MPN is a distinct benign early stage PV. CALR mutated hypercellular thrombocythemia show distinct PMGM bone marrow characteristics of clustered larged immature dysmorphic megakaryocytes with bulky (bulbous) hyperchromatic nuclei, which are not seen in JAK2 mutated ET and PV. MPL mutated normocellular thrombocythemia is featured by clustered giant megakaryocytes with hyperlobulated stag-horn-like nuclei without features of PV in blood and bone marrow. Myeloproliferative disease burden in each of the JAK2, CALR and MPL MPNs is best reflected by the degree of anemia, splenomegaly, mutation allele burden, bone marrow cellularity and myelofibrosis.
Subjects
Genetics & Molecular BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 21 Aug 2018
Clinical, Laboratory, Molecular and Pathobiological (CLMP) criteria for diagnosis of the Myeloproliferative Neoplasms JAK2V617F trilinear polycythemia vera (PV), JAK2 exon 12 PV and JAK2V617F, CALR or MPL mutated thrombocythemias and myelofibrosis
Conference abstract · 28 Aug 2017
Clinical, Laboratory, Molecular and Pathological (CLMP) Euro-Asian classification and treatment options of prefibrotic JAK2, CALR and MPL mutated myeloproliferative Neoplasm
Research article · 2014
2014 WHO Clinical Molecular and Pathological (WHO-CMP) Diagnostic Criteria for the Classification and Staging of Five Distinct JAK2, MPL and CALR Mutated Myeloproliferative Neoplasms
Research article · 2017
Myelofibrosis is a Secondary Event in JAK2 Trilinear Myeloproliferative Neoplasm (MPN) and in CALR and MPL Thrombocythemia: Implications for Novel Treatment Options of Prefibrotic MPN
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectGenetics & Molecular Biology
- BylineArticles whose byline prints “J J Michiels”
